State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines

Charlene M. Dawidczyk, Chloe Kim, Jea Ho Park, Luisa M. Russell, Kwan Hyi Lee, Martin Gilbert Pomper, Peter C. Searson

Research output: Contribution to journalArticle

Abstract

The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.

Original languageEnglish (US)
Pages (from-to)133-144
Number of pages12
JournalJournal of Controlled Release
Volume187
DOIs
StatePublished - Aug 10 2014

Fingerprint

Nanomedicine
Drug Design
Pharmaceutical Preparations
Neoplasms
Nanotechnology
Nanoparticles
Antibodies

Keywords

  • Active targeting
  • Circulation
  • Enhanced permeability and retention (EPR) effect
  • Liposomes
  • Nanoparticles
  • Tumor targeting

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Medicine(all)

Cite this

State-of-the-art in design rules for drug delivery platforms : Lessons learned from FDA-approved nanomedicines. / Dawidczyk, Charlene M.; Kim, Chloe; Park, Jea Ho; Russell, Luisa M.; Lee, Kwan Hyi; Pomper, Martin Gilbert; Searson, Peter C.

In: Journal of Controlled Release, Vol. 187, 10.08.2014, p. 133-144.

Research output: Contribution to journalArticle

Dawidczyk, Charlene M. ; Kim, Chloe ; Park, Jea Ho ; Russell, Luisa M. ; Lee, Kwan Hyi ; Pomper, Martin Gilbert ; Searson, Peter C. / State-of-the-art in design rules for drug delivery platforms : Lessons learned from FDA-approved nanomedicines. In: Journal of Controlled Release. 2014 ; Vol. 187. pp. 133-144.
@article{895a12bf8c4d4d47b55b4575bb9a6de0,
title = "State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines",
abstract = "The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.",
keywords = "Active targeting, Circulation, Enhanced permeability and retention (EPR) effect, Liposomes, Nanoparticles, Tumor targeting",
author = "Dawidczyk, {Charlene M.} and Chloe Kim and Park, {Jea Ho} and Russell, {Luisa M.} and Lee, {Kwan Hyi} and Pomper, {Martin Gilbert} and Searson, {Peter C.}",
year = "2014",
month = "8",
day = "10",
doi = "10.1016/j.jconrel.2014.05.036",
language = "English (US)",
volume = "187",
pages = "133--144",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - State-of-the-art in design rules for drug delivery platforms

T2 - Lessons learned from FDA-approved nanomedicines

AU - Dawidczyk, Charlene M.

AU - Kim, Chloe

AU - Park, Jea Ho

AU - Russell, Luisa M.

AU - Lee, Kwan Hyi

AU - Pomper, Martin Gilbert

AU - Searson, Peter C.

PY - 2014/8/10

Y1 - 2014/8/10

N2 - The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.

AB - The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.

KW - Active targeting

KW - Circulation

KW - Enhanced permeability and retention (EPR) effect

KW - Liposomes

KW - Nanoparticles

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84902136468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902136468&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2014.05.036

DO - 10.1016/j.jconrel.2014.05.036

M3 - Article

C2 - 24874289

AN - SCOPUS:84902136468

VL - 187

SP - 133

EP - 144

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -